Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.

被引：0
|
作者：
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma Catherine
Opalinska, Joanna
机构：
[1] Mem Sloan Kettering Canc Ctr, Myeloma Serv, Dept Med, New York, NY USA
[2] Univ Rochester, Rochester, NY USA
[3] GlaxoSmithKline, London, England
[4] GlaxoSmithKline, Boston, MA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline, Upper Providence, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8073
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
  • [32] Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
    Nooka, Ajay K.
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Routledge, David
    Otero, Paula Rodriguez
    Song, Kevin
    Quach, Hang
    Callander, Natalie
    Minnema, Monique C.
    Trudel, Suzanne
    Jackson, Nicola A.
    Ahlers, Christoph M.
    Im, Ellie
    Cheng, Shinta
    Smith, L.
    Hareth, Nahi
    Ferron-Brady, Geraldine
    Brouch, Maria
    de Oca, Rocio Montes
    Paul, Sofia
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Richardson, Paul
    FUTURE ONCOLOGY, 2021, 17 (16) : 1987 - 2003
  • [33] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
    Baines, Andrea C.
    Ershler, Rachel
    Kanapuru, Bindu
    Xu, Qing
    Shen, Guoxiang
    Li, Liang
    Ma, Lian
    Okusanya, Olanrewaju O.
    Simpson, Natalie E.
    Nguyen, Wanda
    Theoret, Marc R.
    Pazdur, Richard
    Gormley, Nicole J.
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
  • [34] DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Biswas, Swethajit
    Holkova, Beata
    Jackson, Nicola
    Netherway, Thelma
    Paul, Sofia
    Ferron-Brady, Geraldine
    Yeakey, Anne
    Shelton, Chris
    de Oca, Rocio Montes
    Ahlers, Christoph Matthias
    Ballas, Marc S.
    Paul, Elaine Marie
    Gupta, Ira
    Opalinska, Joanna
    Luptakova, Katarina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
    Roussel, Murielle
    Texier, Nathalie
    Germain, Raphael
    Sapra, Sandhya
    Paka, Prani
    Kerbouche, Naima
    Colin, Xavier
    Leleu, Xavier
    BLOOD, 2022, 140 : 4261 - 4263
  • [36] Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    Ferron-Brady, Geraldine
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 851 - 863
  • [37] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Rifkin, Robert M.
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios A.
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania T. M.
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [38] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Stowell, Delia
    Gupta, Ira
    Wu, Frank S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
  • [39] DREAMM-2: Assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma (RRMM).
    Popat, Rakesh
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosima
    Ferrante, Shannon Allen
    Willson, Jenny
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Dimopoulos, M. A.
    Hungria, V. T. M.
    Radino, A.
    Delimpasi, S.
    Mikala, G.
    Masszi, T.
    Li, J.
    Capra, M.
    Matsumoto, M.
    Sule, N.
    Li, M.
    McKeown, A.
    He, W.
    Bright, S.
    Currie, B.
    Boyle, J.
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
12345